Hepatitis (inflammation of the liver) is most often caused by a virus, and the most common types of viral hepatitis in the U.S. are hepatitis A, hepatitis B and hepatitis C. Hepatitis A is curable, but outbreaks still occur in the U.S. with about 3,500 new infections reported each year. Hepatitis B, affects an estimated 1.2 million people, many of whom remain undiagnosed. Hepatitis C is the most prevalent, with nearly 30,000 new infections each year and more than 3 million people currently living with the disease. (Source: CDC website, http://www.cdc.gov/hepatitis/abc/index.htm)
Clinicians now have a wide variety of laboratory tests available to diagnose hepatitis infections and manage affected patients, many of whom require lifelong monitoring. For those living with hepatitis C, new therapies that lead to better patient outcomes are now available, making it more important than ever to identify and treat those with a hepatitis C virus infection.
During this webinar, participants will learn about tests currently being used in the diagnosis and management of hepatitis viruses, current CDC guidelines for hepatitis screening, and the differences between currently available hepatitis C virus assays.
This program is designed for laboratory managers, supervisors, directors and other healthcare professionals involved in hepatitis A, B, or C screening, diagnosis or management.
Denise Uettwiller-Geiger, PhD, DLM(ASCP), Clinical Chemist and Director of Clinical Trials, John T. Mather Memorial Hospital (Port Jefferson, NY)